[2]
DAWSON CR. The chemistry of poison ivy. Transactions of the New York Academy of Sciences. 1956 Mar:18(5):427-43
[PubMed PMID: 13312069]
[3]
SYMES WF, DAWSON CR. Separation and structural determination of the olefinic components of poison ivy urushiol, cardanol and cardol. Nature. 1953 May 9:171(4358):841-2
[PubMed PMID: 13054743]
[4]
McGovern TW, Barkley TM. Botanical dermatology. International journal of dermatology. 1998 May:37(5):321-34
[PubMed PMID: 9620476]
[5]
Stoner JG, Rasmussen JE. Plant dermatitis. Journal of the American Academy of Dermatology. 1983 Jul:9(1):1-15
[PubMed PMID: 6886091]
[6]
Kim Y, Flamm A, ElSohly MA, Kaplan DH, Hage RJ Jr, Hamann CP, Marks JG Jr. Poison Ivy, Oak, and Sumac Dermatitis: What Is Known and What Is New? Dermatitis : contact, atopic, occupational, drug. 2019 May/Jun:30(3):183-190. doi: 10.1097/DER.0000000000000472. Epub
[PubMed PMID: 31045932]
[8]
Epstein WL. Occupational poison ivy and oak dermatitis. Dermatologic clinics. 1994 Jul:12(3):511-6
[PubMed PMID: 7923948]
[9]
Oltman J, Hensler R. Poison oak/ivy and forestry workers. Clinics in dermatology. 1986 Apr-Jun:4(2):213-6
[PubMed PMID: 2941133]
[10]
Rademaker M, Duffill MB. Allergic contact dermatitis to Toxicodendron succedaneum (rhus tree): an autumn epidemic. The New Zealand medical journal. 1995 Apr 12:108(997):121-3
[PubMed PMID: 7739818]
[11]
Williams JV,Light J,Marks JG Jr, Individual variations in allergic contact dermatitis from urushiol. Archives of dermatology. 1999 Aug;
[PubMed PMID: 10456367]
[12]
Gladman AC. Toxicodendron dermatitis: poison ivy, oak, and sumac. Wilderness & environmental medicine. 2006 Summer:17(2):120-8
[PubMed PMID: 16805148]
[13]
Andersen KE, Benezra C, Burrows D, Camarasa J, Dooms-Goossens A, Ducombs G, Frosch P, Lachapelle JM, Lahti A, Menné T. Contact dermatitis. A review. Contact dermatitis. 1987 Feb:16(2):55-78
[PubMed PMID: 3552400]
[14]
Kalish RS. Recent developments in the pathogenesis of allergic contact dermatitis. Archives of dermatology. 1991 Oct:127(10):1558-63
[PubMed PMID: 1929465]
[15]
Barker JN. Role of keratinocytes in allergic contact dermatitis. Contact dermatitis. 1992 Mar:26(3):145-8
[PubMed PMID: 1505178]
[16]
Kupper TS. Production of cytokines by epithelial tissues. A new model for cutaneous inflammation. The American Journal of dermatopathology. 1989 Feb:11(1):69-73
[PubMed PMID: 2644870]
[17]
Kurlan JG, Lucky AW. Black spot poison ivy: A report of 5 cases and a review of the literature. Journal of the American Academy of Dermatology. 2001 Aug:45(2):246-9
[PubMed PMID: 11464186]
Level 3 (low-level) evidence
[18]
Rader RK, Mu R, Shi H, Stoecker WV, Hinton KA. Dermoscopy of black-spot poison ivy. Dermatology online journal. 2012 Oct 15:18(10):8
[PubMed PMID: 23122015]
[19]
Haitz K, Mikailov A, Carter J. Black linear streaks on the face with pruritic plaques on the trunk and arms. Cutis. 2017 May:99(5):E5-E6
[PubMed PMID: 28632804]
[20]
Pittman MA, Lane DR. Black spot poison ivy: under the cover of darkness. The Journal of emergency medicine. 2013 Apr:44(4):e331-2. doi: 10.1016/j.jemermed.2012.11.062. Epub 2013 Feb 16
[PubMed PMID: 23419214]
[22]
Stibich AS, Yagan M, Sharma V, Herndon B, Montgomery C. Cost-effective post-exposure prevention of poison ivy dermatitis. International journal of dermatology. 2000 Jul:39(7):515-8
[PubMed PMID: 10940115]
[23]
Williford PM, Sheretz EF. Poison ivy dermatitis. Nuances in treatment. Archives of family medicine. 1994 Feb:3(2):184-8
[PubMed PMID: 7994440]
[24]
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. The Cochrane database of systematic reviews. 2015 Jul 1:2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2. Epub 2015 Jul 1
[PubMed PMID: 26132597]
Level 1 (high-level) evidence
[25]
Vernon HJ, Olsen EA. A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis. Journal of the American Academy of Dermatology. 1990 Nov:23(5 Pt 1):829-32
[PubMed PMID: 2147698]
[26]
Goodall J. Oral corticosteroids for poison ivy dermatitis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2002 Feb 5:166(3):300-1
[PubMed PMID: 11868634]
[28]
Brodell RT, Williams L. Taking the itch out of poison ivy. Are you prescribing the right medication? Postgraduate medicine. 1999 Jul:106(1):69-70
[PubMed PMID: 10418575]
[29]
Wooldridge WE. Acute allergic contact dermatitis. How to manage severe cases. Postgraduate medicine. 1990 Mar:87(4):221-4
[PubMed PMID: 2138290]
Level 3 (low-level) evidence
[30]
Guin JD. Treatment of toxicodendron dermatitis (poison ivy and poison oak). Skin therapy letter. 2001 Apr:6(7):3-5
[PubMed PMID: 11376396]
Level 3 (low-level) evidence
[31]
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ (Clinical research ed.). 2005 Mar 5:330(7490):516
[PubMed PMID: 15731121]
Level 1 (high-level) evidence
[32]
Amrol D, Keitel D, Hagaman D, Murray J. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2003 Dec:91(6):563-6
[PubMed PMID: 14700441]
[33]
Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy dermatologii i alergologii. 2019 Dec:36(6):752-759. doi: 10.5114/ada.2019.91425. Epub 2019 Dec 30
[PubMed PMID: 31998006]
Level 1 (high-level) evidence
[34]
Baldwin RW, Clegg JA, Curran AC, Austin EB, Khan T, Ma Y, Gunn B, Hudecz F, Byers VS, Lepoittevin JP, Price MR. Regulation of the contact sensitivity response to urushiol with anti-urushiol monoclonal antibody ALG 991. Archives of dermatological research. 1999 Dec:291(12):652-8
[PubMed PMID: 10651166]
[35]
Brook I, Frazier EH, Yeager JK. Microbiology of infected poison ivy dermatitis. The British journal of dermatology. 2000 May:142(5):943-6
[PubMed PMID: 10809852]
[36]
Lee NP, Arriola ER. Poison ivy, oak, and sumac dermatitis. The Western journal of medicine. 1999 Nov-Dec:171(5-6):354-5
[PubMed PMID: 10639874]
[37]
Devich KB, Lee JC, Epstein WL, Spitler LE, Hopper J Jr. Renal lesions accompanying poison oak dermatitis. Clinical nephrology. 1975:3(3):106-13
[PubMed PMID: 124640]
[38]
Marks JG Jr, Fowler JF Jr, Sheretz EF, Rietschel RL. Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite. Journal of the American Academy of Dermatology. 1995 Aug:33(2 Pt 1):212-6
[PubMed PMID: 7622647]
[39]
Grevelink SA, Murrell DF, Olsen EA. Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis. Journal of the American Academy of Dermatology. 1992 Aug:27(2 Pt 1):182-8
[PubMed PMID: 1430354]
[40]
Marks JG Jr, Trautlein JJ, Epstein WL, Laws DM, Sicard GR. Oral hyposensitization to poison ivy and poison oak. Archives of dermatology. 1987 Apr:123(4):476-8
[PubMed PMID: 2950827]
[41]
Epstein WL, Byers VS, Frankart W. Induction of antigen specific hyposensitization to poison oak in sensitized adults. Archives of dermatology. 1982 Sep:118(9):630-3
[PubMed PMID: 6180687]
[42]
Fisher AA. Poison ivy/oak dermatitis. Part I: Prevention--soap and water, topical barriers, hyposensitization. Cutis. 1996 Jun:57(6):384-6
[PubMed PMID: 8804839]
[43]
McGovern TW, LaWarre SR, Brunette C. Is it, or isn't it? Poison ivy look-a-likes. American journal of contact dermatitis : official journal of the American Contact Dermatitis Society. 2000 Jun:11(2):104-10
[PubMed PMID: 10908180]
[44]
Hershko K, Weinberg I, Ingber A. Exploring the mango-poison ivy connection: the riddle of discriminative plant dermatitis. Contact dermatitis. 2005 Jan:52(1):3-5
[PubMed PMID: 15701120]
[45]
Yoo MJ, Carius BM. Mango Dermatitis After Urushiol Sensitization. Clinical practice and cases in emergency medicine. 2019 Nov:3(4):361-363. doi: 10.5811/cpcem.2019.6.43196. Epub 2019 Sep 30
[PubMed PMID: 31763588]
Level 3 (low-level) evidence